Amgen Inc. is halting a study of an experimental drug for reoccurring pancreatic cancer due to disappointing results. The Associated Press reports that a board of medical experts recommended that the Thousand Oaks biotech end the trial because the drug, ganitumab, appears unlikely to help patients live longer.
For reprint and licensing requests for this article, CLICK HERE.
Stories You May Also Be Interested In
- Imaging Clinic Sees Profits With Alzheimer’s Test
- Amgen Cancer Drug Results Disappoint
- Amgen Halts Cancer Drug Trials After Deaths
- Amgen Ends Trials After Deaths
- Amgen-Takeda Drug for Lung Cancer Fails Trial
- Amgen Says Cancer Drug Trial to Resume
- FDA Panel Backs Limited Use of Amgen Bone Drug
- Amgen Lung-Cancer Drug Goes to Trial